Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Bao Yuan Tang Extract and Galactooligosaccharides for Sleep Regulation

NCT07774897 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2026-09-30
Last updated
2026-08-19

Condition(s) studied

Sleep DisturbanceFatigue Syndrome, ChronicEndocrine DisorderGlucose Metabolism DisorderLipid Metabolism Disorders

Investigational drug(s) / intervention(s)

Combination product (Bao Yuan Tang full-component extract 2.0g and galactooligosaccharides 2.0g)Bao Yuan Tang full-component extract 2.0g plus a placebo consisting of maltodextrin 2.0gGalactooligosaccharides 2.0gmaltodextrin placebo 4.0g

Combination product (Bao Yuan Tang full-component extract 2.0g and galactooligosaccharides 2.0g): Participants will receive a combination product consisting of Bao Yuan Tang full-component extract (2.0g) and galactooligosaccharides (2.0g). The intervention will be administered twice daily, one sachet each time, for 3 weeks.

Bao Yuan Tang full-component extract 2.0g plus a placebo consisting of maltodextrin 2.0g: Participants will receive Bao Yuan Tang full-component extract (2.0g) plus a placebo consisting of maltodextrin (2.0g). The intervention will be administered twice daily, one sachet each time, for 3 weeks.

Galactooligosaccharides 2.0g: Participants will receive galactooligosaccharides (2.0g) combined with a maltodextrin placebo (2.0g). The intervention will be administered twice daily, one sachet each time, for 3 weeks.

maltodextrin placebo 4.0g: Participants will receive maltodextrin placebo (4.0g), administered twice daily, one sachet each time, for 3 weeks.

Study summary

Certain classical formulas in traditional Chinese medicine and dietary prebiotics have demonstrated beneficial effects on various aspects of suboptimal health status in previous studies. This research aims to evaluate the effects of Bao Yuan Tang full-component extract combined with galactooligosaccharides on improving health-related outcomes in female registered nurse with suboptimal health status, including sleep disturbances, fatigue, endocrine dysregulation, and glucose and lipid metabolic abnormalities.

Eligibility

Sex
FEMALE
Min age
25 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Female registered nurses aged 25-45 years. * Participants must meet at least one of the following criteria, self-reported presence of at least one target symptom of the trial, including insomnia, daytime fatigue, or difficulty initiating sleep or Pittsburgh Sleep Quality Index (PSQI) score \>7. * Engagement in shift work for at least one month before enrollment, with either ≥ 4 night shifts or ≥32 hours of night-shift work during the preceding month. Exclusion Criteria: * Diagnosed with type 1 or type 2 diabetes mellitus and currently receiving pharmacological treatment. * Diagnosed with clinically thyroid dysfunction, including hyperthyroidism or hypothyroidism, and currently receiving pharmacological treatment. * Diagnosed with Cushing's syndrome, pituitary dysfunction, or other clearly defined endocrine disorders. * Diagnosed with polycystic ovary syndrome (PCOS) and currently receiving pharmacological treatment. * Use of medications that may affect study outcomes, including oral contraceptives, glucose-lowering agents, hormonal medications, hypnotics, lipid-regulating agents, or thyroid hormone preparations, within the past 3 months. * Pregnancy, lactation, or planned pregnancy during the study period. * Confirmed severe organic diseases, such as hepatic or renal insufficiency, cardiovascular disease, or malignancy. * Known allergy to any component of the investigational product. * Use of probiotics, prebiotics, or related traditional Chinese medicine preparations within the past 1 month. * Participation in another clinical trial within the past 3 months. * Planned engagement in vigorous exercise or a weight-management program during the study period. * A previous diagnosis of psychiatric disorders, such as anxiety or depression. * Any condition judged by the investigator to involve communication difficulties, poor compliance, or potential interference with adherence to the study protocol.

Primary outcome measure(s)

  • Pittsburgh Sleep Quality Index (PSQI) — 1 month
    Sleep quality will be assessed the original standard PSQI. The global score ranges from 0 to 21, with higher scores indicating poorer sleep quality. The data will be collected daily from baseline (Day 0) to the end (Day 30).
  • Serum cortisol — Baseline (day 0), Day 10, and Day 21
    Blood samples will be collected at the day of enrollment and 10 and 21 days thereafter to assess changes in serum cortisol levels, the normal reference range is 140-630 nmol/L.
  • Serum total cholesterol and triglyceride — Baseline (day 0), Day 10, and Day 21
    Blood samples will be collected at the day of enrollment and 10 and 21 days thereafter to measure serum total cholesterol and triglyceride levels, the normal reference levels are \<5.2 mmol/L for total cholesterol and \<1.7 mmol/L for triglycerides.

Trial sites (6)

FacilityCityRegionStatus
The First Hospital of Lanzhou University Lanzhou Gansu
The Second Hospital & Clinical Medical School, Lanzhou University Lanzhou Gansu
The Fourth Affiliated Hospital of Hebei University of Traditional Chinese Medicine Shijiazhuang Hebei
Xiangyang Central Hospital Xiangyang Hubei
The Seventh Affiliated Hospital of Xinjiang Medical University Ürümqi Xinjiang
The First People's Hospital of Yunnan Province Kunming Yunnan
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07774897 on ClinicalTrials.gov ↗ ← All trials in China